Ask AI
ProCE Banner Activity

ASCENT-04//KEYNOTE-D19: Phase III Trial of First-line Sacituzumab Govitecan + Pembrolizumab vs Chemotherapy + Pembrolizumab in PD-L1–Positive Advanced TNBC

Conference Coverage
Slideset

In the randomized phase III ASCENT-04//KEYNOTE-D19 trial, SG + pembrolizumab led to a statistically significant and clinically meaningful improvement in PFS vs CT + pembrolizumab in PD-L1–positive advanced TNBC.

Released: June 03, 2025

Expiration: December 02, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Stemline Therapeutics, Inc.